Wright Medical closes rights agreement for BioMimetics buyout
Wright Medical (NSDQ:WMGI) said yesterday that it closed a contingent value rights agreement connected to its acquisition of BioMimetic Therapeutics.
Wright agreed to pay $380 million in cash, stock and milestone payments to pick up BioMimetic and its Augment bone graft back in 2013. The FDA cleared the bone graft with indications as an alternative autograft for ankle and hindfoot fusion procedures in September 2015.
The Amsterdam-based company said that the agreement, dated March 1, 2013 between it and American Stock Transfer & Trust, is terminated effective March 1, according to a press release.
The Augment bone gra...
Source: Mass Device - March 12, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Wall Street Beat wrightmedical Source Type: news
S & amp;N Expands Reach into Regenerative Medicine with M & amp;A
Smith & Nephew is taking a deeper dive into the regenerative medicine market through its $660 million acquisition of Osiris Therapeutics.
The London-based company said it hopes to close the deal in 2Q19 and made the announcement of the pending merger at the American Academy of Orthopedics Annual Meeting held this week in Las Vegas.
Columbia MD-based Osiris Therapeutics delivered revenue of $102 million for the nine-months ended 30 September 2018, an 18.7% increase over the comparable period in 2017. Revenue was $36.5 million for the three-month period ended 30 September 2018, a 22.4% increase year on year. Osiris is ex...
Source: MDDI - March 12, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Orthopedics Source Type: news
Smith and Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc.
LONDON, March 12, 2019 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew plc (LSE: SN,NYSE: SNN), the global medical technology business, announces that it has agreed to acquire Osiris Therapeutics, Inc. (NASDAQ: OSIR), a fast growing company de... Devices, Orthopaedic, Mergers & Acquisitions Smith & Nephew, Osiris Therapeutics, dermal graft, bone graft (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 12, 2019 Category: Pharmaceuticals Source Type: news
Timing of Medicare Loss Linked to Kidney Transplant Outcomes
MONDAY, March 11, 2019 -- Kidney transplant recipients receiving Medicare who lose coverage before or after the current three-year policy time point have an increased risk for allograft loss, according to a study published online March 5 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2019 Category: Pharmaceuticals Source Type: news
Medtronic launches Grafton DBM in Japan
Medtronic (NYSE:MDT) said today that it launched its Grafton demineralized bone matrix bone grafting product in Japan.
The Fridley, Minn.-based company touted the Grafton DBM as the first and only demineralized bone matrix product available in Japan, having won clearance from the country’s PMDA last August.
The newly launched Grafton DBM is a bone graft extender, bone graft substitute and bone void filler intended for use in bony voids or gaps in the skeletal system. The company added that the Grafton DBM has consistently high osteoconductivity scores and that it is the “most utilized and scientifically-studie...
Source: Mass Device - February 28, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured Orthopedics Spinal Medtronic Source Type: news
Orthofix wins FDA PMA nod for M6-C artificial cervical disc
Orthofix (NSDQ:OFIX) said yesterday that it won FDA approval for its M6-C artificial cervical disc, intended for treating patients suffering from cervical disc degeneration.
The Lewisville, Texas-based company said that the M6-C artificial cervical disc was developed by Spinal Kinetics, which it acquired last April.
The newly cleared M6-C is a next-gen artificial disc intended to replace an intervertebral disc damaged by cervical disc degeneration. The system is designed to restore physiological motion to the spine and is indicated as an alternative to cervical fusion, Orthofix said.
Pre-market approval of the device cam...
Source: Mass Device - February 8, 2019 Category: Medical Devices Authors: Fink Densford Tags: Featured Food & Drug Administration (FDA) Pre-Market Approval (PMA) Regulatory/Compliance Spinal Orthofix Source Type: news
Sirakoss wins CE Mark for Osteo3 bone graft substitute
Sirakoss said yesterday that it won CE Mark clearance in the European Union for its Osteo3 novel nanosynthetic bone graft substitute.
The Aberdeen, Scotland-based company said that its Osteo3 consists of an inorganic matrix intended to be completely reabsorbed into the bone.
Sirakoss added that the newly cleared bone graft substitute features a unique surface chemistry designed to catalyze rapid and complete bone regeneration following a fracture or for support after corrective surgeries.
“Osteo3 is the first of our new generation of bone substitute products to receive CE Mark, a major milestone for Sirakoss. We bel...
Source: Mass Device - February 1, 2019 Category: Medical Devices Authors: Fink Densford Tags: Orthopedics Regulatory/Compliance sirakoss Source Type: news
Plasma Marker Predicts Allograft Failure in Lung Transplant
THURSDAY, Jan. 24, 2019 -- Donor-derived cell-free DNA (ddcfDNA) is a potential biomarker that can predict allograft failure after lung transplantation, according to a study published online Jan. 23 in EBioMedicine.
Sean Agbor-Enoh, M.D., Ph.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 24, 2019 Category: Pharmaceuticals Source Type: news
Bioventus launches Osteomatrix+ bone graft
Bioventus announced today that it has started selling Osteomatrix+ – a moldable bone graft substitute intended for a variety of orthopedic and spine bone remodeling applications.
Bioventus officials boast that Osteomatrix+ has improved moldability, flexibility and versatility versus its predecessor.
“Osteomatrix+ represents the first of several next-generation products that will be added to the Bioventus portfolio in the next five years,” Bioventus CEO Tony Bihl said in a news release.
Get the full story on our sister site Medical Design & Outsourcing.
The post Bioventus launches Osteomatrix+ bone graft appear...
Source: Mass Device - January 17, 2019 Category: Medical Devices Authors: Chris Newmarker Tags: Business/Financial News News Well Orthopedics Bioventus LLC Source Type: news
New RBI for Kidney Allografts: Can It Replace Routine Tests? New RBI for Kidney Allografts: Can It Replace Routine Tests?
Dr Desai reviews a study examining the usefulness of a new renal biopsy index (1-RBI). Could it be used in place of invasive routine biopsies in deceased-donor kidney transplant recipients?Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 14, 2019 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news
Pirfenidone in RAS After Lung Transplantation Pirfenidone in RAS After Lung Transplantation
How might pirfenidone benefit lung transplant recipients with restrictive allograft syndrome?American Journal of Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 10, 2019 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news
New Data Boosts Value Proposition of AlloSure
When our kidneys fail to function as they should, our treatment options generally begin with dialysis and end with a kidney transplant. Unfortunately, transplanted kidneys last, on average, between 12 years and 15 years (depending on if the donor is living or deceased, and if they are a relative or not). Some recipients are lucky if they even get five good years out of their transplanted kidney.
CareDx has already established the clinical value of AlloSure, a donor-derived cell-free DNA test designed to assess allograft health in kidney transplant patients, and new data demonstrates the test's clinical utility in patients ...
Source: MDDI - January 9, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: IVD Source Type: news
Kuros raises $16m for bone-growth protein
Kuros Biosciences (SIX:KURN) said this week that it raised more than $16 million for clinical trial of its bone-growth protein as it expands the commercial footprint for its MagnetOs bone graft substitute.
Proceeds from the CHF 16.1 million round are earmarked for a Phase II trial of the Fibrin-PTH protein in spinal fusion procedures and for the commercialization of MagnetOs, which won 510(k) clearance from the FDA in August 2017 and CE Mark approval in the European Union in May. Kuros won CE Mark approval in the European for its Neuroseal dural sealant in June 2017.
The Zurich-based company said it plans to launch the s...
Source: Mass Device - December 19, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Orthopedics Regenerative Medicine kurosbiosciences Source Type: news
Hamstring injuries in Major League Baseball pitchers: implications in graft selection for ulnar collateral ligament reconstruction - Howard DR, Banffy MB, Elattrache NS.
BACKGROUND:: Hamstring tendons are commonly harvested as autograft for ulnar collateral ligament reconstruction. There is no consensus in the literature whether the hamstring tendon should be harvested from the ipsilateral (drive) leg or contralateral (lan... (Source: SafetyLit)
Source: SafetyLit - December 19, 2018 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
MiMedx accounting firm quits
The troubles at MiMedx (NSDQ:MDXG) continued last week with the resignation of the accounting firm tapped to audit its books in the wake of a financial scandal.
Marietta, Ga.-based MiMedx last July ousted ex-CEO Parker Petit and president & COO William Taylor amid a board-directed independent investigation that had already prompted the departure of CFO Michael Senken and treasurer John Cranston in June.
At the time, MiMedx said it would restate all of its earnings reports going back to 2012 and was cooperating with U.S. Securities & Exchange Commission and Justice Dept. investigations into the matter.
The comp...
Source: Mass Device - December 10, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Regenerative Medicine Wall Street Beat MiMedx Group Inc. Source Type: news
